• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.73% Nasdaq Up0.90%

    Advaxis, Inc. (ADXS)

    10.51 Up 0.20(1.94%) 4:00PM EDT
    |After Hours : 10.51 Down 0.00 (0.02%) 5:06PM EDT
    ProfileGet Profile for:
    Advaxis, Inc.
    305 College Road East
    Princeton, NJ 08540
    United States - Map
    Phone: 609-452-9813
    Fax: 609-452-9818
    Website: http://www.advaxis.com

    Index Membership:N/A
    Full Time Employees:20

    Business Summary 

    Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate designed to target the PSA antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate for the treatment of Her2 expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Advaxis, Inc.

    Corporate Governance 
    Advaxis, Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 5. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 3; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Daniel J. O'Connor Esq., 50
    Chief Exec. Officer, Pres and Director
    Mr. Gregory T. Mayes Esq., 46
    Chief Operating Officer and Exec. VP
    Dr. Robert G. Petit Ph.D., 55
    Chief Scientific Officer and Exec. VP
    Ms. Sara M. Bonstein MBA, 34
    Chief Financial Officer and Sr. VP
    Dr. David J. Mauro M.D., Ph.D., 50
    Chief Medical Officer and Exec. VP
    Mr. Mayo Pujols ,
    VP of Manufacturing
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders